

---

# Gestational Trophoblastic disease study updates


---

**Professor Michael J Seckl**

**GCIIG Chicago meeting Jun '17**

# GOG-0275: A PHASE III RANDOMIZED TRIAL OF PULSE ACTINOMYCIN-D VERSUS MULTI-DAY METHOTREXATE FOR THE TREATMENT OF LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA


Study Chair: Julian Schink, MD



**Opened June '12. 57/381 recruited: closed Sep '16**

# Phase II trial of anti-endoglin antibody (TRC105) without or with bevacizumab in relapsed high risk GTN

30 patients



Inclusion criteria:

- High risk GTN
- Elevated hCG or Measurable PSTT/ETT
- $\geq 1$  prior multi agent regimen
- PS  $\leq 1$

Opening Nov '16

## Participating ISSTD Member Institutions

- Brigham & Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Charing Cross Hospital, Imperial College, London, UK
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

# **Phase II trial of anti-endoglin antibody (TRC105) without or with bevacizumab in relapsed high risk GTN**

## **Primary Endpoint:**

- ORR to TRC105 ± Bevacizumab**

## **Secondary Endpoints:**

- PFS**
- ORR to bev in patients refractory to TRC105**
- evaluate formation of anti-TRC105 antibodies**
- evaluate PK of TRC105 and bev**
- assess toxicity**
- assess angiogenic biomarkers**

**4 patients recruited: 1 CR and 2 PD and 1 starting**